University Venture Fund

University Venture Fund — Investment

Funds long-run capital for Cambridge-affiliated deep-tech and life science spinouts.

The University Venture Fund is Cambridge Enterprise's primary direct equity vehicle for investing University of Cambridge capital into spinouts and commercial innovations derived from University research. The fund has operated since 1995 and received an additional £30 million University commitment in 2020, of which £10 million is ring-fenced for sustainability-focused investments. All returns are reinvested rather than distributed, making the structure evergreen and ensuring University capital continues to compound within the Cambridge innovation system. Ticket size is not publicly disclosed; engagement proceeds through the Cambridge Enterprise technology transfer team rather than through an open application portal.

Eligibility is restricted to companies that originate from, or are directly derived from, University of Cambridge research — external ventures without a Cambridge IP or affiliation basis are not considered. The fund invests across the full early-stage journey from pre-seed through Series A and beyond, covering deep tech, life sciences, and sustainability sectors. Notable portfolio companies include Riverlane (quantum error correction), Nu Quantum (which reached a $60 million Series A), T-Therapeutics, Cambridge Electric Cement, Carbon Re, Nyobolt, and Seprify. The fund co-invests with the University of Cambridge Enterprise Fund series (UCEF I through X, totalling £30.4 million raised from alumni and associates), which doubles the capital deployed per deal.

Because the University Venture Fund invests University balance-sheet capital directly, terms and ticket sizes are negotiated case-by-case through Cambridge Enterprise rather than set by a published schedule. Founders seeking investment should initiate contact through the Cambridge Enterprise commercialisation and tech transfer team, which conducts initial assessment before progressing to investment committee review. The fund's evergreen structure means there is no fixed fundraising window or annual deadline; live deals are assessed on a rolling basis throughout the year.